Evidence map›Paper›PMID 20008638›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.

Grzegorz S Nowakowski, Matthew J Maurer, Thomas M Habermann, Stephen M Ansell, William R Macon, Kay M Ristow, Cristine Allmer, Susan L Slager, Thomas E Witzig, James R Cerhan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  5. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cardiovascular and Cancer Risk: The Role of Cardio-oncology.Journal of the advanced practitioner in oncology · 2018
    Review
  14. Review
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Grzegorz S NowakowskiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. Nowakowski.Grzegorz@mayo.edu
Matthew J Maurer
Thomas M Habermann
Stephen M Ansell
William R Macon
Kay M Ristow
Cristine Allmer
Susan L Slager
Thomas E Witzig
James R Cerhan
Mayo Clinic · US

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
NCI NIH HHS P50 CA097274NCI NIH HHS P50CA97274
6 · The paper itself

Abstract

purposeStatins have antilymphoma properties but have also been shown to inhibit the binding of rituximab to the CD20 antigen, resulting in reduced antitumor activity of rituximab in vitro. The clinical impact of statin use on the outcome of lymphoma patients treated with a rituximab-containing regimen is unknown. PATIENTS AND

methodsConsecutive patients with newly diagnosed, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were enrolled onto a registry and observed prospectively. The impact of statin use on patients' outcomes was analyzed.

resultsTwo hundred twenty-eight patients with DLBCL and 293 patients with FL were enrolled from September 2002 through June 2007; 21% of patients with DLBCL and 19% of patients with FL were on statins at diagnosis, and 20% and 17% remained on statins during lymphoma treatment, respectively. All patients with DLBCL and 39% of patients with FL received initial therapy containing rituximab. The median follow-up time was 47 months (range, 13 to 80 months). Statin use had no impact on the overall response rate (P = .67), overall survival (P = .76), or event-free survival (EFS) in patients with DLBCL (hazard ratio [HR] = 0.85; 95% CI, 0.43 to 1.68). Statin use at diagnosis was associated with improved EFS in patients with FL (HR = 0.45; 95% CI, 0.26 to 0.77), including subgroups treated with rituximab or a rituximab-containing regimen (HR = 0.38; 95% CI, 0.14 to 1.07) and patients who were observed only (HR = 0.38; 95% CI, 0.17 to 0.84).

conclusionThe concurrent use of statins during the treatment of patients with DLBCL and FL in the rituximab era did not adversely affect outcome. The apparent benefit of statin therapy on FL outcome requires further studies.

Indexed as

AgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsDrug InteractionsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMalePrognosisRituximabAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsRituximab

Identifiers

PMID20008638
PMCPMC2815703
OpenAlexW2171848487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.